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COGNITIVE BEHAVIORAL THERAPY AGE EFFECTS IN
CHILD AND ADOLESCENT ANXIETY: AN INDIVIDUAL
PATIENT DATA METAANALYSIS
Kathryn Bennett, Ph.D.,1∗ Katharina Manassis, M.D.,2,3 Stephen D. Walter, Ph.D.,1 Amy Cheung, M.D.,3
Pamela Wilansky-Traynor, Ph.D.,3,4 Natalia Diaz-Granados, MSc.,1 Stephanie Duda, BSc.,1 Maureen Rice, M.A,
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Background: Investigations of age effects on youth anxiety outcomes in random-
ized trials (RCTs) of cognitive behavior therapy (CBT) have failed to yield a clear
result due to inadequate statistical power and methodologic weaknesses. We con-
ducted an individual patient data metaanalysis to address this gap. Question:
Does age moderate CBT effect size, measured by a clinically and statistically
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significant interaction between age and CBT exposure? Methods: All English
language RCTs of CBT for anxiety in 6–19 year olds were identified using
systematic review methods. Investigators of eligible trials were invited to submit
their individual patient data. The anxiety disorder interview schedule (ADIS)
primary diagnosis severity score was the primary outcome. Age effects were in-
vestigated using multilevel modeling to account for study level data clustering
and random effects. Results: Data from 17 of 23 eligible trials were obtained
(74%); 16 studies and 1,171 (78%) cases were available for the analysis. No
interaction between age and CBT exposure was found in a model contain-
ing age, sex, ADIS baseline severity score, and comorbid depression diagnosis
(power ≥ 80%). Sensitivity analyses, including modeling age as both a cate-
gorical and continuous variable, revealed this result was robust. Conclusions:
Adolescents who receive CBT in efficacy research studies show benefits comparable
to younger children. However, CBT protocol modifications routinely carried out
by expert trial therapists may explain these findings. Adolescent CBT protocols
are needed to facilitate the transportability of efficacy research effects to usual
care settings where therapists may have less opportunity for CBT training and
expertise development. Depression and Anxiety 30:829–841, 2013. C© 2013
Wiley Periodicals, Inc.
Key words: anxiety disorders; cognitive behavior therapy; child/adolescent;
treatment; empirical supported treatment
INTRODUCTION
Anxiety disorders affect 6–7% of those under 18 years
of age[1,2] and are associated with debilitating conse-
quences. These include poor school performance, dis-
rupted relationships with peers and adults, and dimin-
ished participation in the normal activities of childhood
and adolescence.[3] Relatively few children and youth
are affected by only one type of anxiety disorder,[4] and
there is frequent comorbidity with other disorders, par-
ticularly depression and substance abuse.[5] Anxiety that
begins before age 18 often persists into adulthood,[6–8]
especially in the presence of comorbid conditions such
as depression,[9] resulting in a lifetime of diminished
life quality characterized by failed adult relationships,
poor labor market participation, reduced income, and
increased need for social welfare assistance.
Cognitive behavioral therapy (CBT) is the psy-
chotherapeutic treatment of choice for children and
youth with anxiety and mood disorders. Eight research
syntheses,[10–17] including three metaanalyses, report
that compared to waitlist or attention controls in ran-
domized controlled trials (RCTs), CBT is an efﬁcacious
treatment when administered by highly trained experts
to carefully screened samples of children and youth un-
der ideal conditions. These authors also report that the
efﬁcacy of individual and group CBT treatment ap-
proaches (either with or without parent involvement) is
not signiﬁcantly different. Despite this strong research
base, a number of authors have questioned whether the
levels of beneﬁt observed (e.g. anxiety diagnosis remis-
sion rates) apply equally to children and adolescents.[12]
First, there is reason to believe that the CBT proto-
cols evaluated in these trials may be developmentally
inappropriate for adolescents because many were cre-
ated for children under age 12 and then adapted for use
in adolescents. Consequently, effect size estimates based
on all children aged 6–19 may mask age-related clini-
cal heterogeneity and thus overestimate the beneﬁts of
CBT in adolescents. Second, adolescents may have in-
creased severity of disorder and be less responsive to
treatment. For example, teens may be struggling with
the effects of prolonged untreated anxiety including en-
trenched anxiety-related avoidance, chronic depression,
substance abuse, andmore severe anxiety.[3] Finally, high
need for autonomy by teens, compared to younger chil-
dren, may result in poor engagement and compliance
leading to reduced treatment beneﬁt in adolescents.
Three of the available research syntheses consider the
issue of developmental appropriateness, but conclusions
regarding whether age moderates CBT treatment effect
cannot be drawn. Compton et al.[11] reports that one of
21 studies reviewed investigated the effect of age and re-
ported a signiﬁcant positive effect. James et al.[15] calls
for further studies that include adolescents and inves-
tigate age effects. Hudson[12] concludes some evidence
exists that age moderates CBT effect size, but calls for
further studies. Finally, it is worthy of note that despite
lack of clarity regarding age effects, the recent CAMS
trial (Child/adolescent anxiety multimodal study) used a
separate CBT protocol for adolescents.[18,19]
When we reviewed the individual CBT RCTs in-
cluded in the available reviews, we found six studies that
reported ﬁndings regarding the inﬂuence of age onCBT
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treatment outcomes. Most reports suffered from sig-
niﬁcant methodologic weaknesses, namely the conduct
of unplanned subgroup analyses with insufﬁcient power
to rigorously test for an interaction, the appropriate
statistical method for assessing treatment effect
moderators.[20] In fact, only three of the six studies tested
for an interaction between age andCBT treatment effect
with one of the three reporting a statistically signiﬁcant
positive ﬁnding.
It is widely recognized that individual trials are rarely
designed with adequate levels of power to conduct sub-
group analyses and test for interaction effects.[21] How-
ever, the availability of a substantial number of rigorous
trials of a speciﬁc intervention, such as CBT for child
and adolescent anxiety, offers great potential to advance
knowledge through the conduct of an individual patient
data metaanalysis (IPDMA). This gold standard meta-
analysis technique calls for patient level data to be ob-
tained for all relevant RCTs and combined in a common
dataset.[22–24] The resulting larger sample size provides
increased power and enables a more meaningful inves-
tigation of treatment effect moderators because ﬁndings
based on individual trials might change in IPDMA anal-
yses using larger sample sizes.
Accordingly, we conducted an IPDMA to address the
question: Does age moderate CBT effect size, as mea-
sured by a clinically and statistically signiﬁcant interac-
tion between age and the effect of CBT exposure? In
particular, is CBT effect size attenuated in adolescents
compared to younger children in the currently available
RCTs? Our goal was to clarify the extent to which the
beneﬁt of CBT extends equally to children and adoles-
cents. An answer to this question is relevant to good
clinical practice. It is also relevant to the development
of knowledge translation strategies that aim to ensure
the transportability of CBT treatment effects observed
in efﬁcacy studies to anxious adolescents who seek help
in usual care settings.[25]
METHODS
TRIAL SEARCH STRATEGY
Cochrane[26] and PRISMA[27] (preferred reporting items for sys-
tematic reviews and metaanalyses) methods were used to identify eli-
gible CBTRCTs as follows: (i) electronic data-bases (OVID-Medline,
OVID-Embase, OVID-Cochrane Central, OVID-PsycINFO, and
EBSCO CINAHL) were searched for the period 1990 to 2011 to
identify existing systematic reviews and metaanalyses of the efﬁcacy
of CBT in child and adolescent anxiety (key words and a replica-
ble strategy created by an experienced research librarian available
from the author); (ii) reference lists of the eight published system-
atic reviews/metaanalyses identiﬁed were hand searched to identify
RCTs; these existing reviews included potentially eligible primary
RCTs published from 1966 to 2005; (iii) additional RCTs published
from 2005 onwards were then identiﬁed by searching the same elec-
tronic databases (key words and search strategy available from the au-
thor); (iv) reference lists of all eligible RCTs identiﬁed were hand
searched; and (v) all collaborating authors reviewed the list and noted
omissions.
STUDY ELIGIBILITY
Published primary studies that met the following criteria were el-
igible: (i) RCT comparing CBT to waitlist or attention controls; (ii)
common CBT protocol used for all study participants; (iii) English
language; (iv) participants aged 6–19; (v) baseline diagnosis: anxiety
disorder (excluding OCD and PTSD) or clinically elevated levels of
anxiety as deﬁned by the author; (vi) outcome assessments include one
or more of: (a) presence of anxiety diagnosis; (b) severity of anxiety di-
agnosis; (c) self-report or parent-reportmeasures of anxiety symptoms;
(vii) face-to-face CBT implemented by any service provider (excluding
self-help and parent implemented CBT).
STUDY SELECTION AND DATA EXTRACTION
K.B. and S.D. screened potentially eligible studies (titles and
abstracts) and extracted study level data from all eligible studies. Dis-
agreements were resolved through discussion.
COMMON DATASET
Senior investigators of all eligible RCTs were invited to contribute
their individual patient data using a common template. Study level vari-
ables (e.g. number of CBT sessions, service provider, setting, parental
involvement in CBT sessions, etc.) were extracted from published
study reports by two reviewers (K.B. and S.D.). Disagreements were
resolved through discussion.
INDIVIDUAL PATIENT ELIGIBILITY
Participants in obtained eligible studies were included in the
IPDMA if they had complete data for the variables required for the
primary analysis (see below).
VARIABLES AND MEASURES—PRIMARY
ANALYSIS
Anxiety Disorder Severity Score. The primary outcome mea-
sure was the anxiety disorder interview schedule[28] (ADIS) clinical
severity rating score at posttreatment for the primary, targeted di-
agnosis (identiﬁed at baseline), hereafter denoted as ADIS-CSR-PT.
The baseline ADIS clinical severity rating score was used as a covari-
ate, hereafter denoted as ADIS-CSR-B. The ADIS is a semistructured
interview that assesses anxiety, mood, and externalizing disorders and
generates impairment/severity ratings measured on a scale of 0–8 for
each diagnosis. Child and parent versions are available. Inter-rater re-
liability is good[28] and evidence of responsiveness to treatment effect
is available.[29,30]
Age. Four categories (6–7; 8–11; 12–15; and 16–19 years of age)
were selected a priori, reﬂecting the theoretical basis of our hypoth-
esis that developmental stage moderates CBT treatment effect. The
reference category was 8–11 years because CBT protocols were devel-
oped for this age group. We hypothesized that those who are younger
or older then 8–11 years would respond differently to CBT (i.e. cog-
nitive limitations in the younger children and the special challenges
associated with treating adolescents as outlined in the introduction).
In addition to this theoretical foundation, a categorical representa-
tion provides maximal power to detect an interaction between age and
treatment effect.
Sex. Sex was included as a covariate, since female sex predicts
worse treatment outcomes.[3,5]
Depression. Baseline ADIS depression diagnosis was included
as a covariate, since comorbid depression predicts worse anxiety treat-
ment outcomes.[9,31]
CBT Exposure. Study participants who received individual or
group CBT, with or without parent involvement, of any duration, and
by any type of service provider were classiﬁed as exposed to CBT.
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Control Group Conditions. Study participants assigned to a
waitlist or attention control group were classiﬁed as controls.
SENSITIVITY ANALYSIS VARIABLES AND
MEASURES
The robustness of our results was tested using alternative measures
of (i) anxiety disorder/symptoms and (ii) age as follows:
AnxietyDisorder Status. Presence of anADIS anxiety diagnosis
(yes/no) at posttreatment was used.
Anxiety Symptoms. The child behavior checklist (CBCL) inter-
nalizing t-scores (parent report) and the revised child manifest anxi-
ety scale (RCMAS) total anxiety t-scores (self-report) at posttreatment
were used as alternative outcome measures in multi-indicator sensitiv-
ity analyses, because these were the most frequently applied symptom
scales in the trials. Baseline CBCL or RCMAS were included as co-
variates when these variables were used as outcomes. Both the CBCL
and RCMAS are psychometrically valid and reliable measures of child
and adolescent anxiety.[32,33]
Age. Sensitivity analyses were conducted using age as a continu-
ous variable (including linear, quadratic, and cubic terms).
STATISTICAL METHODS
Data from each trial were received and checked for completeness
and missing values. Final analyses were based on all patients random-
ized using the intention to treat principle. Any queries raised were
resolved by contacting the trial investigator. Analyses were performed
on the data as provided with no imputation for missing data. In stage
one of the metaanalysis of individual patient data, random-effects lin-
ear regression models stratiﬁed by study were ﬁtted, and included the
interaction of the effect of CBT with age group on ADIS-CSR-PT
at the study level. Individual study results were presented using forest
plots.[34] In stage two analyses, linear random-effectsmodels for the ag-
gregate effects ofCBTexposure onADIS-CSR-PTand age group sub-
group analyses were investigated with random-effects using multilevel
modeling (to allow for treatment heterogeneity between studies).[35]
Multilevel regression models were constructed using restricted maxi-
mum likelihood where individuals (level 1) were nested within studies
(level 2). Between study differences were assessed through twomodels:
(1) random interceptmodel at the study level; (2) random-effectsmodel
where CBT treatment effect was allowed to vary between studies. Our
study question was addressed by conducting a series of prespeciﬁed
models that evaluated CBT treatment effect and the age group by
CBT interaction term on ADIS-CSR-PT, adjusting for ADIS-CSR-
B, age group, baseline depression diagnosis, and sex. The estimated
residual variance was calculated for each model. Formal comparisons
of ﬁt between simpler andmore complexmodels were conducted using
the Bayesian information criterion (BIC) statistic. The BIC accounts
for model complexity (number of parameters included), and enables
the derivation of likelihood ratio tests for pairs of models that are
Figure 1. PRISMA flow diagram of eligible studies (and individuals).
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TABLE 1. Individual study characteristics
≥12 Anxiety Comorbid CBT
Groups** Age years Female disorders depression sessions Provider Setting
Study* (n) years (%) (%) included*** (%) (child) qualiﬁcations**** School Clinic
1. Group CBT (6) 13–18 100.0 58.3 SP with 67% having 0.0 12 A
√
Waitlist (6) other comorbid
anxiety disorder
2. Child CBT (28) 6–14 21.5 43.0 SAD Data not 12 B
√
CBT + FAM1 (25) OAD available
Waitlist (26) SP
3. Child CBT (53) 8–17 54.8 59.3 All 20.0 13 C
√
Family CBT (57)
Waitlist (25)
4. Group CBT (61) 7–13 12.5 72.7 All 0.0 10 B
√
Control (67)
5. Individual CBT (12) 8–14 32.4 48.6 GAD 5.4 18 B
√
Group CBT (10) SP
Waitlist (15) SAD
6. Group CBT (4) 15–18 100.0 88.9 All 22.2 10 B
√
Group attention (5)
7. Group CBT (60) 6–16 32.1 42.9 All 2.7 10 B
√
Group attention (52)
8. Individual CBT (55) 7–14 24.2 44.1 GAD 9.9 16 B
√
Family CBT (56) SAD
Family attention (50) SP
9. Individual CBT (29) 9–14 41.5 41.5 OAD 13.2 16 B
√
Waitlist (24) SAD
AD
10. Individual CBT (71) 8–14 36.8 42.4 OAD 5.6 16 B
√
Waitlist (54) SAD
AD
11. SASS2 (21) 13–17 100.0 73.8 SP with ≥43% 0.0 12 B √
Waitlist (21) having other
comorbid anxiety
disorder
12. SASS2 (19) 14–16 100.0 83.3 SP with 33% having 13.9 12 B
√
Group attention (17) other comorbid
anxiety disorder
13. Child CBT (29) 7–17 38.0 50.6 SAD 21.5 12 B
√
Child and parents SP
CBT (30) GAD
Waitlist (20) PD ± A
14. Group CBT (90) 6–15 4.1 39.7 All 7.9 9 B
√
Bibliotherapy (90)
Waitlist (87)
15. Group CBT (37) 5–18 28.6 41.1 SP 7.1 12 B
√
Waitlist (19) OAD
GAD
16. EBCM3 (40) 6–16 20.2 48.1 Phobias (simple, 5.8 10 B
√
EBCSC4 (41) social, and
ES5 (23) Agoraphobia) with
≥49% having
other comorbid
anxiety disorder
17. Clinic CBT (22) 7–14 19.4 41.7 All 1.4 10 B
√
Clinic and internet
CBT (27)
Waitlist (23)
*see Appendix; **1, family anxiety management training; 2, skills for academic and social success; 3, exposure-based contingency management;
4, exposure-based cognitive self-control; 5, education support control; ***AD, avoidant disorder; GAD, generalized anxiety disorder; OAD, over-
anxious disorder; PD ± A, panic disorder with or without Agoraphobia; SAD, separation anxiety disorder; SP, social phobia; ****A, psychiatric
social worker and psychiatry residents; B, psychologist(s) and graduate student(s); C, health care psychologists, psychotherapists, and behavioral
therapists.
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hierarchically structured.[36] All analyses were conducted using SAS v.
9.2.[37] Signiﬁcance was considered at P < .05; multiple comparisons
were adjusted using the Bonferroni method.
Power calculations postulated differences in treatment effect be-
tween the 8–11-year-old reference group, and each of the 6–7, 12–15,
and 16–19-year-old groups. Mean differences of ≥2 on the ADIS-
CSR-PTwere judged to be aminimum clinically important difference.
Weassumed the estimatedgroupmeanswerenormally distributed, and
used a derived value of 0.34 for the residual (between person) standard
deviation on the ADIS-CSR-PT. Study power was then calculated in
the usual way from the standard normal distribution theory, adopting
a null hypothesis of equal treatment effects in each pair of age groups
being compared.[21]
RESULTS
Figure 1 shows the PRISMAﬂowdiagram.Our search
strategy identiﬁed 878 records after duplicates were re-
moved; 89 records remained after level 1 and 2 screening
of titles and abstracts. Following full-text screening, 23
RCT’s met our inclusion criteria. We obtained datasets
for 17 of them (74%) (see Appendix for reference list).
Among the 1,507 cases included in the 17 studies, 91
were excluded because they received self-help CBT or
their exposure status could not be conﬁrmed; 245 cases
were excluded due to missing data (Fig. 1 contains spe-
ciﬁc reasons). The remaining 1,171 cases included 16
of the trials and 77.7% of all cases potentially available
in the 17 studies obtained. The six eligible but not ob-
tained datasets included 265 participants (147 CBT; 118
control subjects) or 14.9% of all individuals who could
potentially be included in our analyses. Reasons for non-
inclusion were: the data was no longer available (4); non-
response of author (2).
Table 1presents descriptive information for the 17ob-
tained studies. The percentage of participants aged ≥ 12
years variedbetween studies from4.1 to 100%.Similarly,
the percentage with comorbid depression varied from 0
to 22.2% and the number of CBT sessions provided var-
ied from 9 to 18 between studies. CBT providers were:
psychologists and graduate students in 88% of studies,
psychiatric social workers, and psychiatry residents in
6%of studies, andhealth care psychologists, psychother-
apists, and behavioral therapists in the remaining 6%.
Regarding setting, 76.5% of studies provided treatment
in a clinic setting while 23.5% utilized school settings.
The anxiety disorders included are listed for each study.
All studies used the ADIS to assess anxiety status. Ten
(59%) also assessed anxiety symptoms using the CBCL
parent report; while 8 (47%) also used theRCMAS (child
report). Ethnicity could not be included in our analyses
Figure 2. Study level mean differences in ADIS-CSR-PT adjusted by ADIS-CSR-B.
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because of substantivemeasurement differences between
trials, and 29% did not report it at all. Similarly, only
53% of studies reported on family structure or income,
precluding the inclusion of indicators of socioeconomic
status (SES) in our analytic models. All but one study
included some type of parental involvement in the CBT
intervention tested, so this variable was not included
as a covariate. The most commonly reported exclusion
criteria were as follows; 11/17 studies excluded partici-
pants with psychosis; 10/17 studies excluded participants
taking psychotropic medication; 3/17 studies excluded
participants who experienced a change to their dose of
psychotropic medication; and 8/17 studies excluded par-
ticipants with physical or intellectual disabilities. The
study level characteristics of the six unobtained studies
were summarized similarly (seeTable 3 in theAppendix).
Their exclusion appears unlikely to have introduced bias
into the IPDMA results.
Figure 2 presents a forest plot of study level results for
our primary outcome measure—between group mean
difference in ADIS-CSR-PT and the 95% conﬁdence
interval (adjusted for ADIS-CSR-B). Twelve (75%) of
the 16 study level results were statistically signiﬁcant.
Figure 3 presents a forest plot of study level results for
age group by CBT treatment interaction (adjusted for
ADIS-CSR-B). Only two studies revealed statistically
signiﬁcant interactions corresponding to differences be-
tween the 12–15 year and the 8–11-year-old age groups.
Only one study included participants in all four age
groups in both the CBT and control groups, but no sta-
tistically signiﬁcant age by CBT treatment interaction
was found between any of the three other age groups
and the 8–11 year reference age group. The variabil-
ity in interaction estimates within studies was evident
and called for pooling study results in phase 2 of the
analysis.
Table 2 shows results for the sevenmodels evaluated in
the phase 2 pooled analysis. Results for eachmodel show,
as appropriate, the variance between studies for the in-
tercept (between-study differences in the mean ADIS-
CSR-PT), and treatment slope (between study variabil-
ity of treatment effect). The main effects of treatment
(included in models 1–7) and ADIS-CSR-PT (included
in models 3–7) are statistically signiﬁcant in all models
tested. There is also signiﬁcant variation between studies
in treatment effect (slope), representing 13% of the total
variance explained. The age group by CBT treatment
interaction tested in model 5 was not statistically signif-
icant and had little to no effect on the BIC and other
model parameters compared to model 4. Figure 4 in the
Appendix presents a forest plot of the age group ﬁndings
relative to the 8–11 year age group.
Similar ﬁndings emerged when baseline depression
diagnosis and sex were added (model 6). These covari-
ates remain statistically insigniﬁcant when the treatment
by age interaction is removed (model 7). The coefﬁ-
cients for CBT treatment and ADIS-CSR-B are stable
across all models, indicating no substantial confounding
of the main effects by other variables. As can be seen, the
BIC changes very little as additional variables are intro-
duced into the model. Hence, these additional variables,
while themselves potentially statistically signiﬁcant, do
not substantially increase the amount of explained vari-
ation in the outcome data.
Figure 3. Treatment effects by age group (adjusted for ADIS-CSR-B).
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TABLE 2. Random effects model for ADIS-CSR-PT
Model
2 5 6 7
1 Treatment 3 4 Treatment, Treatment, Treatment,
Treatment (random Treatment, Treatment, ADIS-CSR-B, ADIS-CSR-B, age, ADIS-CSR-B,
(random treatment and ADIS-CSR-B, Age and sex, depression, age, sex, and
Variable intercept) slope) ADIS-CSR-B and Age interaction and interaction and depression
Intercept, beta (SE) 4.53 (0.25)*** 4.62 (0.29)*** 4.62 (0.25)*** 4.52 (0.25)*** 4.61 (0.27)*** 4.46 (0.28)*** 4.38 (0.26)***
CBT treatment, beta
(SE)
–1.98 (0.14)*** –2.11 (0.35)*** –2.17 (0.34)*** –2.16 (0.34)*** –2.32 (0.37)*** –2.18 (0.37)*** –2.05 (0.33)***
ADIS-CSR-B, beta
(SE)
– – 0.47 (0.06)*** 0.47 (0.06)*** 0.47 (0.06)*** 0.49 (0.06)*** 0.48 (0.06)***
Age (years; ref:
8–11), beta (SE)
– – – 0 (–) 0 (–) 0 (–) 0 (–)
6–7 – – – 0.04 (0.24) 0.11 (0.35) –0.09 (0.38) 4.96 × 10-3 (0.26)
12–15 – – – 0.11 (0.16) –0.28 (0.27) –0.15 (0.28) 0.14 (0.17)
16–19 – – – 0.71 (0.33)* 0.84 (0.59) 0.86 (0.59) 0.66 (0.34)
Depression (ref:
absent), beta (SE)
– – – – – 0.41 (0.26) 0.42 (0.26)
Sex (ref: female),
beta (SE)
– – – – – 0.22 (0.14) 0.22 (0.14)
Interactions – – – –
Treatment * age
group (years; ref:
8–11), beta (SE)
– – – – 0 (–) 0 (–) –
6–7 – – – – –0.15 (0.48) 0.16 (0.52) –
12–15 – – – – 0.59 (0.34) 0.45 (0.35) –
16–19 – – – – 0.19 (0.71) –0.28 (0.71) –
Random effects
Variance between
studies (SE)
0.77 (0.31)** 0.38 (0.35) 0 (–) 0 (–) 0 (–) 0 (–) 0 (–)
Variance of
treatment slopes
(SE)
– 0.75 (0.34)* 0.72 (0.23)** 0.69 (0.23)** 0.72 (0.24)** 0.63 (0.22)** 0.62 (0.22)**
Residual variance
(SE)
5.35 (0.22)*** 5.02 (0.21)*** 4.78 (0.20)*** 4.78 (0.20)*** 4.77 (0.20)*** 4.81 (0.21)*** 4.81 (0.21)***
Model parameters
BIC 5,329.1 5,282.1 5,218.4 5,217.1 5,212.1 4,888.4 4,892.0
*P-value <.05, **P<.01, ***P<.001.
Note: Baseline severity centered.
SENSITIVITY ANALYSES
The Table 2 analyses were repeated using: (i) three
alternative treatment outcome measures [posttreatment
presence of the primary targeted ADIS anxiety
diagnosis (binary outcome: yes/no), CBCL and RCMAS
symptom scale t-scores]; and (ii) age as a continuous vari-
able. All results conﬁrmed the ﬁndings of the main anal-
ysis were robust; that is, no statistically signiﬁcant age
by CBT treatment effect interaction (results available
from author). Finally, we investigated the possibility of a
three-way interaction between sex, age, and CBT treat-
ment, but it was not signiﬁcant (details not shown).
POWER
Power calculations carried out before examination of
the data revealed the following. With the sample size of
1,171 achieved and considering age group comparisons
with the 8–11 year group, we estimated the power to
detect a clinically important difference of 2 scale points
on the ADIS-CSR to be: 99% (6–7 years), >99% (12–
15 years), and 80% (16–19 years). For a 3-scale point
change: 99% (6–7 years), 99% (12–15 years), and 99%
(16–19 years). Finally for completeness, for a one-scale
point change, power was estimated at 55% (6–7 years),
84% (12–15 years), and 29% (16–19 years).
DISCUSSION
Individual trials of CBT for child and adolescent anxi-
ety have not clariﬁedwhether adolescents enjoy the same
level of beneﬁt from CBT as do younger children pri-
marily due to inadequate power. The IPDMA reported
here addresses this knowledge gap. We obtained data
from 16 (74%) of all eligible RCTs that compared CBT
to a waitlist or attention control group in youth aged
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6–19 years with an anxiety diagnosis. Tests for an in-
teraction between age and the effect of CBT exposure
(n = 1,171 cases) were not statistically signiﬁcant show-
ing that age does notmoderateCBTtreatment outcomes
in carefully controlled efﬁcacy studies.
The lack of evidence for an age effect is encourag-
ing in that outcomes for children and youth treated by
therapists in efﬁcacy RCTs appear unlikely to be af-
fected by possible developmental mismatches associated
with the content of CBT protocols. However, the ab-
sence of an interaction effect may be because therapists
who participate in efﬁcacy studies have the skills needed
to adapt available treatment manuals to the needs of
adolescents, and accordingly ensure the efﬁcacy of the
CBT experience. In fact, 10 of 17 investigators who con-
tributed data to our IPDMA conﬁrmed that their study
therapists routinely tailored CBT protocols to meet
adolescent needs. Consequently, despite the absence of
an age effect in our IPDMA of efﬁcacy RCTs, critical
questions remain regarding the inﬂuence of age on CBT
outcomes in usual care. It is possible that clinicians work-
ing in these settings may be less skilled in adapting CBT
protocols to adolescents, or be unaware of the need to
do so. For example, the scant research available suggests
that most children and youth with mental health prob-
lems are not seen by specialist providers.[38] Moreover,
it is known that the quality of usual child and adoles-
cent mental health care is uneven and that the beneﬁts
observed in efﬁcacy research may not be realized in rou-
tine, community care settings due to a rangeof barriers to
transportability.[25,39,40] In fact, some evidence is begin-
ning to emerge that treatment outcomes may be better
in university compared to community settings, but few
studies are currently available.[41]
STRENGTHS AND LIMITATIONS
The strengths of our study include the following. First,
the sample size required to test interaction effects in indi-
vidual trials is approximately four times greater than that
needed to assess main effects,[21] and it is often difﬁcult
in grant requests to provide a compelling scientiﬁc ra-
tionale to justify the associated increased costs. IPDMA
methods provide amuch-needed alternative that enables
the achievement of greater power by combining individ-
ual patient data from individual RCTs.
Second, IPDMA is the gold standard approach to
metaanalysis and we were able to achieve the high level
of collaboration needed for success. The high response
rate from eligible investigators, with 17 of 23 (74%)
requested datasets obtained, reﬂects the high enthusi-
asm in the ﬁeld for projects like this. In fact, four more
datasets would have been contributed, had they not been
lost. Third, the high response rate also limits the po-
tential for bias in our ﬁndings. When we examined the
published results of the unobtained datasets, we foundno
compelling evidence that they might have changed our
results. Similarly, among the eligible studies obtained
we were able to include 78% of the individual cases in
our primary analysis. The availability of the ADIS in
all studies was a fourth strength, allowing us to avoid
the methodologic complications associated with creat-
ing a common outcome measure derived from different
measures of the same construct. Sensitivity analyses con-
ducted using other measures of anxiety outcomes (RC-
MAS, CBCL, and presence/absence of anxiety disorder)
revealed that our results were robust to the choice of anx-
iety outcome. Fifth, whenwe repeated our analyses using
age as a continuous variable, the results did not change.
Sixth, we included key covariates in the models tested
including baseline anxiety severity and the presence of
depression. Finally, we used random effects models that
provide a conservative approach to the analysis.
At the same time, our study is not without limitations.
It was unfortunate that we could not include key socio-
demographic variables (e.g. SES and ethnicity) in the
models we tested due to lack of data in original studies.
Investigators are encouraged to increase the attention
paid to including them in future studies. Second, we did
not look at age effects for speciﬁc diagnoses because the
potential to do so was limited in the available studies,
and the careful analysis required was beyond the scope
of the present report. Although there is some variation
in the prevalence of speciﬁc disorders at different ages, it
is possible that the high comorbidity among anxiety dis-
orders in children and the frequent inclusion of multiple
disorders in the same treatment protocols could obscure
age-related diagnostic effects. Third, we could be criti-
cized for not conducting multiple exploratory subgroup
analyses to consider the full range of possible CBTmod-
erators. In contrast, supported with peer-reviewed fund-
ing,1 our objective was to address a single, theory driven
research question established a priori, and to obtain a
methodologically rigorous result of direct relevance to
the quality of clinical care and knowledge translation
priorities (i.e. barriers to effective, evidence-based prac-
tice). Numerous authors have pointed out the pitfalls of
subgroup analysis, including the risk of false negatives
(due to inadequate power) and false positives (due to
multiple signiﬁcance testing).[21,42] To have considered
multiple possiblemoderators is at best exploratory and at
worst simply data dredging. Fourth,we could not include
the CAMS trial because two different CBT protocols
were used—one for children and one for adolescents—
and therefore CAMS does not provide a test of age ef-
fects. Fifth, our analysis focused on end-of-treatment
outcomes only. Age effects at posttreatment follow-up
were not investigated. Sixth, we did not consider the
effect of family/parent involvement because all trials ex-
cept one included some typeof family/parent component
in their CBT protocol. It is worthy of note that three of
the 17 included studies identiﬁed the use of family CBT
(study 2, 3, and 8).However, since the age ranges in these
1Bennett K. Prevention and intervention in adolescent anxiety: a re-
search synthesis. Canadian Institutes of Health Research, Research
Synthesis Grant ($100,000). 2008.
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studies (i.e. 6–14, 8–17, and 7–14) are not different from
the age ranges in the remaining studies, it is unlikely
that their inclusion had an impact on our results. A ﬁnal
point concerns the inﬂuence of parental anxiety and ac-
commodation on our results. Both of these factors may
vary by age (e.g. interfering with exposure in younger
children; limiting age-appropriate autonomy in adoles-
cents) and are therefore worthy of therapeutic attention
at all ages. It is unclear whether or not their inﬂuence
would interact with age in predicting outcome.
CONCLUSIONS
Our IPDMA results are encouraging and show that
when adolescents receive CBT in efﬁcacy research stud-
ies they beneﬁt at a level similar to younger children.
However, CBT protocol modiﬁcations routinely carried
out by therapists who participate in RCTs may explain
these ﬁndings. The development and evaluation of pro-
tocols tailored to the unique needs of adolescents could
facilitate the transportability of effective CBT to adoles-
cents seen in usual care settings, where therapists may
have less opportunity for CBT training and develop-
ment of the needed expertise. First, protocols need to
consider adolescent increased cognitive sophistication,
skepticism of adults’ ideas, desire for autonomy, and fo-
cus on interpersonal (especially peer) issues relative to
younger children.[43] Second, they need to recognize
that complex presentations are common in usual care
settings (in contrast to efﬁcacy studies), are characterized
by increased anxiety severity and comorbidity, and ne-
cessitate the provision of CBT in the context of a larger
treatment plan that may include other interventions.[40]
Finally, therapist training and supervision is generally
less in routine compared to academic settings, and ther-
apists in usual care may face organizational and ﬁnan-
cial constraints not found in academic centers.[44,45] All
of these factors have the potential to signiﬁcantly affect
the transportability of currently availableCBTprotocols
and hence, the potential for adolescents with anxiety to
beneﬁt.
Anxiety disorders are a signiﬁcantmental health prob-
lem among children and youth. They are of particular
concern for adolescents who may be struggling with the
effects of prolonged untreated disorder andmay result in
the cooccurrence of depression and substance abuse. A
better understanding of the factors that are most likely
to inﬂuence the transportability of CBT to usual care
settings holds great promise for better anxiety outcomes
and improved quality of life in adolescence and adult-
hood.We hope the IPDMA reported here stimulates the
ﬁeld to move forward in this direction, and to engage in
knowledge translation research that aims to ensure the
beneﬁts of CBT are reaped broadly by children, youth,
and families.
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Figure 4. Age x treatment group interaction for four developmental age groups (model 5).
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